Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
European Journal of Nuclear Medicine and Molecular Imaging2000Vol. 27(7), pp. 766–777
Citations Over TimeTop 1% of 2000 papers
Gregory A. Wiseman, Christine A. White, Michael Stabin, William L. Dunn, William D. Erwin, Magnus Dahlbom, Andrew Raubitschek, Kastytis C. Karvelis, Timothy E. Schultheiss, Thomas E. Witzig, Richard E. Bélanger, Stewart Spies, Daniel Silverman, Judy Berlfein, Eric Ding, Antonio J Grillo-López
Related Papers
- → Current Concepts and Future Directions in Radioimmunotherapy(2010)15 cited
- → Ibritumomab tiuxetan for non-Hodgkin’s lymphoma(2006)23 cited
- → Ongoing Trials with Yttrium 90–Labeled Ibritumomab Tiuxetan in Patients with Non-Hodgkin's Lymphoma(2004)9 cited
- → Radioimmunotherapy for Non-Hodgkin's Lymphoma With Yttrium 90 Ibritumomab Tiuxetan(2002)11 cited
- → Features of Ibritumomab as Radionuclide Therapy(2018)